Physician profile
Timothy W Prestley
NPI 1548421803
$209,895.10
in general payments reported to CMS, 2019-2025
73 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,857 · 2020: $16K · 2021: $26K · 2022: $24K · 2023: $51K · 2024: $34K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Food and Beverage: $18K · Consulting Fee: $1,525 · Travel and Lodging: $1,478 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,718.75 |
| Food and Beverage | $17,887.99 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $1,478.17 |
| Education | $106.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159,386.98 | 2021-2025 | |
| Allergan, INC. | $15,181.32 | 2019-2022 | |
| Pfizer INC. | $10,123.96 | 2019-2025 | |
| Ucb, INC. | $2,379.82 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,148.62 | 2019-2025 | |
| Csl Behring | $1,146.40 | 2019-2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $1,053.01 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $1,010.15 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sk Life Science, INC. | $1,000.66 | 2020-2025 | |
| Argenx US, INC. | $978.04 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $933.95 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $886.86 | 2020-2025 | Vyepti, Rexulti |
| Merz Pharmaceuticals, LLC | $872.60 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Biogen, INC. | $842.79 | 2019-2025 | Leqembi, Aduhelm |
| Otsuka America Pharmaceutical, INC. | $825.45 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
Show all 72 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Prestley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.